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the development of diabetic nephropathy, and no studies addressed this issue among Egyptian pop-
ulation. The results of angiotensin converting enzyme gene (ACE) in the susceptibility to nephrop-
athy in type 1 diabetes with nephropathy are conﬂicting. We aim to identify the associations of two
ACE gene polymorphisms (PstI, A > G substitution and a 287-bp insertion/deletion) with
nephropathy in type 1 diabetes in Egyptian children/adolescents. Our case-control study contained
140 diabetic individuals; 80 diabetic with nephropathy as cases, and 60 diabetic subjects without
nephropathy as control group. Ampliﬁed DNA from peripheral leucocytes/buccal mucosa was gen-
otyped for using polymerase chain reaction and enzymatic assay. We found no signiﬁcant differ-
ences in the distribution of ACE insertion/deletion and PstI genotypes or allele frequencies were
observed between the examined groups. Frequencies of PstI–indel haplotypes were similar in all
of our study groups. In both cases and control subjects, ACE activity and microalbuminuria were
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ciation between the ACE gene I/D and PstI polymorphisms with nephropathy in type 1 diabetes.
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Diabetes mellitus (DM), a multifactorial chronic disease, has
rapidly increased to epidemic proportions over the past few dec-
ades. The number of patientswithDMworldwidewas estimated
at 173 million in 2002 and is predicted to increase to 350 million
cases by 2030 (www.who.int/whr/2006/en) [1]. The disease is
associated with severe complications including nephropathy,
neuropathy, retinopathy and accelerated cardiovascular dis-
ease. Nephropathy is a frequent complication of long-term dia-
betes. Diabetic nephropathy is the leading cause of end-stage
renal disease (ESRD) in developed countries (www.who.int/
whr/2006/en) [1]. It is the major determinant of premature mor-
bidity and mortality in insulin-dependent diabetes mellitus
(IDDM) [2]. About 30% of IDDM (known as type 1 diabetes
‘T1D’) patients is susceptible to diabetic nephropathy [3],
characterized by hypertrophy of glomeruli, hyperperfusion,
thickening of basement membranes and glomerular hyperﬁltra-
tion [4]. In addition, there is microalbuminuria and subse-
quently progressive glomerulosclerosis, and tubulointerstitial
ﬁbrosis causing reduction in glomerular ﬁltration rate (GFR)
may occurs later [5,6]. The majority of patients with T1D will
either develop nephropathy within the ﬁrst 15 years after diag-
nosis or will remain relatively protected thereafter [3].
Differential disease risk in diabetic nephropathy may be
partly attributable to genetic susceptibility. Evidence for a ge-
netic component to diabetic nephropathy comes from family
studies displaying familial aggregation of diabetic nephropathy
both in type 1 and in type 2 diabetes mellitus [7–9], as well as
differences in the prevalence of diabetic nephropathy between
ethnic groups [8,9].
Some variants have been used to associate the genotypeswith
diabetic nephropathy [10]. These include the following genes:
angiotensin converting enzyme (ACE, MIM 106180), apolipo-
protein E (APOE, MIM 107741), erythropoietin (EPO, MIM
133170), nitric oxide synthase (NOS3, MIM 163729), heparan
sulfate proteoglycan (HSPG2, MIM142461), vascular endothe-
lial growth factor A (VEGFA, MIM 192240), ferm domain-
containing 3 (FRMD3, MIM 607619), and cysteinyl-tRNA
synthetase (CARS, MIM 123859).
ACE gene, located on chromosome 17q23, comprises 26
exons; exons 1–12 encode for the amino domain, exons
13–26 encode for the carboxyl domain. The ﬁrst polymorphism
found in this genewas a 287-bp insertion/deletion (indel) located
in intron 16, and the D allele was associated with higher serum
ACE activity [11], together with enhanced conversion of angio-
tensin I to angiotensin II [12], inactivation of bradykinin [13]
and more rapid progression of renal disease [14]. Five other
polymorphisms (1Dde, 2RsaI, 2RsaII, 4AluI, and 4AluII) in
the ACE gene were identiﬁed by Doria et al. [15].
Some reports supported the ACE indel polymorphism with
the development of diabetic nephropathy [16,17], while some
studies did not conﬁrm this ﬁnding [18,19]. Representationof cases from Egypt was abandoned; none from the Egyptian
subjects with nephropathy of type 1 diabetes investigated the
association of genetic variations of ACE gene polymorphisms.
Here, the current study presents a genetic risk of the ACE
gene polymorphisms with nephropathy in type 1 diabetes
among Egyptian children/adolescents.
2. Subjects and methods
2.1. Eligibility criteria
We searched for studies comparing genetic variants in type 1
diabetes (T1D) with nephropathy, relative to T1D patients
without nephropathy. We limited our analyses to studies inves-
tigating established and advanced diabetic nephropathy. A
standard questionnaire was used to obtain the medical history
and demographic data to patients attending the Pediatrics
Hospital in Ain Shams University, Cairo.
2.2. Subjects
All individuals recruited (n= 140; male 74, female 66) with
T1D were born of Egyptian parents and lived in Cairo Gover-
norate. A physical examination contained height, weight and
blood pressure measurements (Table 1). In addition retinopa-
thy status was assessed by reviewing medical records.
Individuals with nephropathy (n= 80; microalbuminuria
cases = 70 plus overt nephropathy cases = 10) had diabetes
for at least 10 years before the onset of persistent proteinuria
(>0.5 g protein/24 h), hypertension (blood pressure > 140/
90 mmHg and/or treatment with anti-hypertensive medication)
and diabetic retinopathy.
Microalbuminuria could be considered if the albumin/cre-
atinine ratio ranged from 30 to 299 lg/mg. Overt nephropathy
was deﬁned if the albumine/creatinine ratio was >300 lg/mg.
Normoalbuminuria was classiﬁed if values <30 lg/mg [20].
Individuals recruited as control subjects (n= 60) had T1D
for a minimum duration of 15 years were not taking anti-
hypertensive medication and did not demonstrate any evidence
of renal disease. The presence of non-diabetic renal disease was
exclusion criteria for this collection.
Blood samples were drawn for biochemical determinations
and for isolation of DNA. The study protocol was approved
by the ethics committee of the same institute, and a parental
informed consent was obtained prior to documenting individ-
uals in the study.
2.3. Methods
2.3.1. HbA1c measurement
Mean glycosylated hemoglobin (HbA1c) as a reﬂection of
long-term glycemic control was determined using high perfor-
Table 1 Clinical characteristics in type 1 diabetic individuals with nephropathy (cases) and without nephropathy (controls).
Characteristics Cases (n= 80) Controls (n= 60) p-Value
Age (years) 14.4 ± 2.3 13.7 ± 2.4 0.1
Disease duration (years) 10.8 ± 2.4 8.1 ± 2.0 <0.05
HbA1c (%) 9.30 ± 2.5 7.1 ± 2.0 <0.001
BMI (kg m2) 27.9 ± 6.9 32.5 ± 5.0 >0.05
Systolic blood pressure (mmHg) 147.0 ± 12.5 127.0 ± 14.9 <0.001
Diastolic blood pressure (mmHg) 83.0 ± 11.5 75.0 ± 12.4 <0.001
Random blood glucose (mg/dl) 170.6 ± 65.8 144.5 ± 56.2 <0.05
ACE (IU/l) 71.0 ± 25.6 13.7 ± 2.4 <0.0001
Microalbuminuria (lg/mg) 98.0 ± 66.0 19.4 ± 7.2 <0.0001
Null genetic risk of ACE gene polymorphisms with nephropathy in type 1 diabetes among Egyptian population 189mance liquid chromatography (HPLC) using the VARIANT
II Hemoglobin Testing System (Bio-Rad Laboratories, Hercu-
les, CA, USA).
2.3.2. Determination of the albumin/creatinine ratio
The albumin excretion rate was determined in three 24-h urine
collections performed at least 1 month apart. The urine sam-
ples were stored at 4 C and assayed within 1 week. Urinary
albumin was determined by enzyme-linked immunosorbent as-
say (ELISA). The urinary creatinine was determined using
automated a Kodak Ektachem 700 Analyzer (Rochester,
NY, USA).
2.3.3. Serum ACE activity measurement
Serum ACE activity was measured by a kinetic assay on the
basis of converting angiotensin I into angiotensin II using a
colorimetric ACE kit (Bu¨hlmann Laboratories AG, Baselstr.,
Switzerland). We used ACE high sensitive assay (order code:
KK-ACF) with a detection limit of 1 U/l. A 250 ll of the sub-
strate was added to 25 ll of each calibrator, control and serum
patient sample and the reaction mixture was incubated at
37 C for 5 min and the color was measured at 340 nm twice
in a time interval of exactly 10 min. One unit of ACE activity
is deﬁned as the amount of enzyme required to release 1 lmol
of hippuric acid expressed as nmol/ml/min. Serum sample
from individuals of 20–70 years were collected. The serum
range (mean ± SD) has been determined to be 12–68 ACE
unit.
2.3.4. DNA isolation
Genomic DNA was extracted from peripheral blood (200 ll)
using the QIAamp DNA Blood kit (Qiagen, Hilden, Germany).
In some cases, DNA was prepared in situ by gently scraping
the buccal mucosa for 30 s using a cytobrush [21]. The cells
obtained were treated directly with diluted NaOH solution,
heated, and neutralized with Tris-Cl, pH 8.0. A 2.5-ll volume
of buccal cells typically sufﬁced for ampliﬁcation by polymerase
chain reaction (PCR).
2.3.5. ACE gene genotypes
We selected two polymorphic regions; intron 7 (amino
domain) and intron 16 (carboxy domain) loci. The PstI poly-
morphism was analyzed using the ﬂanking primers 50-CTC
GGC TTG GGA CTT CTA-30, and the anti-sense 50-AGA
GCT GGT CCA TCG TGA-30 [22]. Genotyping for the indel
polymorphism was performed using a PCR fragment ampliﬁed
by the sense 50-CTG GAG ACC ACT CCC ATC CTT TCT-30and anti-sense oligo 50GAT GTG GCC ATC ACA TTC GTC
AGA T-30 [23].
For PCR ampliﬁcation, DNA was added to a 25-ll reaction
mixture containing 0.1 lM of each primer, 200 mM of each
dNTP, 67 mM Tris–HCl, 16 mM (NH4)2SO4, 0.01%
Tween-20, 1 mM MgCl2, and 0.45 U Taq DNA polymerase.
The samples were then subjected to 30 rounds on PCR Engine
Dyad (Bio-Rad Laboratories, USA) with annealing tempera-
ture at 58 C for either indel or PstI polymorphism for
1 min, followed by ﬁnal extension of 7 min at 72 C. The
PCR amplicon of intron 7 was digested with PstI restriction
enzymes (New England Biolabs, Beverly, MA, USA) at
37 C for 2 h. The product was separated on a 3% MetaPhor
agarose gel (BMA, Rockland, ME, USA), stained by ethidium
bromide and photographed using a gel-documentation system
(G-Box, SynGene, Frederick, MD, USA). The () allele was
detected as a single band (800 bp), and the (+) allele was
detected as two fragments (600 bp and 200 bp). Fragments of
450 bp and 190 bp indicate the presence of the insertion/dele-
tion heterozygous status, respectively.
2.3.6. ACE haplotypes
The two polymorphisms were also analyzed jointly, and the
haplotype frequencies were compared between the study
groups. Frequencies of haplotypes in the groups were calcu-
lated according to pairwise distribution of I/D and PstI
genotypes.
2.4. Data analysis
Statistical analysis was performed using the SPSS 16.0 (SPSS,
Chicago, IL, USA). The data are presented as mean ± stan-
dard deviation. Nonparametric measures were used to calcu-
late chi-square values. A probability <0.05 was considered
statistically signiﬁcant. Odds ratios with 95% conﬁdence inter-
vals were calculated.
3. Results
Eighty nephropathy with type1 diabetes (T1D) cases and 60
T1D controls without nephropathy were recruited in this study.
The diabetic nephropathy cases had age ranges from 7 to 18
years (mean, 14.4 ± 2.3 years), and their duration of diabetes
were 5–14 years (mean, 10.8 ± 2.4 years). The diabetic controls
had age ranges from 6 to 18 years (mean, 13.7 ± 2.4 years), and
their duration of diabetes were 5–10 years (mean, 8.1 ± 2.0
years). There was no signiﬁcant difference between cases and
Table 2 Genotypes distribution and allele frequencies of ACE gene polymorphisms in nephropathy with type 1 diabetic individuals.
Variable Cases (%) n= 80 Controls (%) n= 60 v2 (p-value)
PstI polymorphism
‘+/+’ 50 (62.5) 44 (73.3) 0.3 (0.59)
‘+/’ 24 (30.0) 10 (16.7) 2.0 (0.18)
‘/’ 6 (7.5) 6 (10.0) 0.14 (0.71)
v2 (p-value) 18.4 (p< 0.0001) 18.6 (p< 0.0001)
PstI allele frequency
‘+’ 124/160 (0.77) 98/120 (0.82) > 0.05
‘‘ 36/160 (0.23) 22/120 (0.18) > 0.05
Indel polymorphism
‘D/D’ 38 (47.5) 30 (50.0) 0.03 (0.87)
‘I/D’ 30 (37.5) 18 (30.0) 0.33 (0.56)
‘I/I’ 12 (15.0) 12 (20.0) 0.29 (0.59)
v2 (p-value) 6.65 (p= 0.036) 2.6 (p= 0.27)
Indel allele frequency
‘D’ 106/160 (0.66) 78 (0.65) > 0.05
‘I’ 54/160 (0.34) 42 (0.35) > 0.05
Table 3 Frequencies of PstI and indel ACE haplotypes in the study groups.
Population Combined genotypes
n ++/DD +/DD  /DD ++/ID +/ID  /ID ++/II +/II  II
Control 60 20 4 6 12 6 0 12 0 0
Cases 80 20 12 6 18 12 0 12 0 0
Haplotypes (frequency)
n + D  D + I  I
Control 96 50 (0.52) 16 (0.17) 30 (0.31) 0 (0.0)
Cases 140 74 (0.53) 24 (0.17) 42 (0.30) 0 (0.0)
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dex (BMI) (Table 1). Clearly, the diabetic nephropathy had
higher systolic/diastolic blood pressure (147/83 mmHg)
compared to controls (127/75 mmHg) with a high signiﬁcant
difference (p< 0.001). Signiﬁcant differenceswere found higher
in duration of diabetes and inHbA1c for cases compared to con-
trols (p< 0.001). Moreover, serum ACE activity and microal-
buminuria were signiﬁcantly higher in diabetic nephropathy
cases compared to diabetic controls (<0.0001 each).
In the present study, the associations between ACE gene
polymorphisms in intron 7 (PstI) and in intron 16 (indel) and
diabetic nephropathy were examined separately (Table 2). The
PstI ‘+/+’ genotype was a more frequent genotype (63.3%)
than ‘+/’ (30%) and ‘/’ (6.7%). The differences of the
genotype distributions in cases were independently signiﬁcant
(v2 = 18.4, 2 df, p< 0.0001). The difference was due to an ex-
cess of PstI ‘+/+’ homozygotes. The differences between the
PstI genotypes in cases and controls were not signiﬁcant
(p> 0.05 each).
For the indel polymorphism among the diabetic nephropa-
thy, the D/D genotype in the ACE gene was a more frequent
genotype (47.5%) than I/D (37.5%) and I/I (15%), with a sig-
niﬁcant difference (v2 = 6.65, 2 df, p= 0.036), while the geno-
type distributions in control group were not signiﬁcantly
different (v2 = 2.6, 2 df, p= 0.27) (Table 2). All indel possible
genotypes were not signiﬁcant compared to these genotypes in
diabetic control group (p> 0.05 each).Although the frequencies of the ‘+’ allele or the ‘D’ allele
were themost frequent in cases or controls independently; all al-
leles in this study were not deﬁned as a risk factor in diabetic
nephropathy cases compared to diabetic controls (>0.05 each)
(Table 2).
Table 3 showed the possible combined genotypes in the two
ACE polymorphisms in the study. Combined haplotypes
showed that the frequencies of the different PstI–indel haplo-
types were similar in all of our study groups (Table 3).
In both cases and control subjects, ACE activity and micro-
albuminuria were highest among D/D homozygotes and low-
est in I/I homozygotes, with I/D heterozygotes having
intermediate values (Table 4). A dissimilar relationship was
shown for PstI genotypes, in which the ACE activities were
nearly comparable (Table 4). There were no differences in
the ACE activity between cases and control subjects.4. Discussion
The present study provides the ﬁrst data on the genetic risk of
ACE gene polymorphisms in type 1 diabetes with nephropathy
in Egyptian population. Our study focused on thePstI (in intron
7) and indel (in intron 16) loci, whichwe found, linked the risk of
diabetic nephropathy in Egyptian children/adolescents. To our
knowledge, only three studies in literature dealt with the effect of
Table 4 Serum ACE levels in groups with different ACE genotypes.
ACE genotypes (n= 80) Total number of cases Serum ACE activity (IU/l) Microalbuminuria (lg/mg)
PstI polymorphism
’+/+’ 50 84.9 ± 50.0* 139.0 ± 66.2
‘+/’ 24 82.7 ± 26.5* 115.5 ± 47.2
‘/’ 6 73.1 ± 19.8 64.8 ± 17.8
Indel polymorphism
D/D 38 89.8 ± 19.2* 140.0 ± 47.0*
I/D 30 57.5 ± 12.4* 59.9 ± 23.3
I/I 12 55.4 ± 29.2 55.0 ± 19.4
Values are mean±SD.
* p< 0.001 versus I/I genotype by Student’s t-test.
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Jewish ethnic population [24–26].
The ‘+/+’ genotype showed a more likely higher fre-
quency rather than other genotypes in diabetic individuals with
nephropathy (cases) and without nephropathy (controls). We
found no association between the PstI alleles or genotypes in
cases in the studied group. This is in agreement with Grzeszc-
zak et al. in this issue [24].
A similar results were coming up with the ‘D’ allele in the
ACE indel polymorphism. The latter ﬁnding is in agreement
of other studies [18,19,26,27] that found no associations with
the D allele and diabetic nephropathy. Unexpected results in
Malays have been reported that there is a likely higher I/I
genotype frequency in this ethnic population [28].
Interestingly, we also found an independent association be-
tween indel genotypes and diabetic nephropathy among the
Egyptians. Although the ‘+/+’ and the ‘D/D’ genotypes were
generally the most frequent type of ACE polymorphisms, the
probabilities of these genotypes as potential predictors for dia-
betic nephropathy is highly unlikely. In addition, the D/D, I/
D, I/I genotypes were previously demonstrated to display high-
est, intermediate and lowest levels of serum ACE levels, respec-
tively [11]. However, the DD genotype has always been held
accountable for exerting its deleterious effects on various dis-
ease pathogenesis including diabetic nephropathy.
In this study, all potential clinical risk factors including dia-
betes duration, blood pressure, HbA1c, ACE activity, and
microalbuminuria that might have predictive effects for dia-
betic nephropathy, while gender, age of subjects, and BMI
had no effect on the development of diabetic nephropathy.
5. Conclusion
We conclude that in this study the role of the ACE PstI (in in-
tron 7) and insertion/deletion (in intron 16) in the susceptibil-
ity to diabetic nephropathy was not demonstrated. Potential
clinical risk factors of diabetes duration, blood pressure,
HbA1c, ACE activity, and microalbuminuria did not alter
the null inﬂuences of ACE PstI and indel polymorphisms on
disease patterns in our population. Although statistically sufﬁ-
cient sample sizes were used in the present study, this sample
size might be considered too small to permit any conclusion
about the two PstI–indel haplotypes associated in the risk of
diabetic nephropathy.Conﬂict of interest
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